Article Text

Download PDFPDF
Optimally Debulked Stage III Ovarian Cancer: Intraperitoneal or Intravenous Chemotherapy?
  1. Michael Friedlander, PhD, FRACP
  1. Department of Medical Oncology, The Prince of Wales Hospital, Randwick, NSW, Australia.
  1. Address correspondence and reprint requests to Michael Friedlander, PhD, FRACP, Department of Medical Oncology, The Prince of Wales Hospital, High Street Randwick, NSW 2031, Australia. E-mail: michael.friedlander{at}


The optimal management of women with optimally debulked stage III ovarian cancer is contentious. There are in particular widely differing views regarding the role of intraperitoneal chemotherapy, and this has been debated widely. Being on the negative side in the debate, I will provide compelling reasons why systemic chemotherapy should remain the standard of care but argue that dose-dense weekly paclitaxel rather than the 3 weekly schedules should be adopted based on the results of the Japanese Gynecologic Oncology Group study. The pharmacokinetics of intraperitoneal paclitaxel suggests that intraperitoneal paclitaxel at day 8 with intravenous paclitaxel at day 1 is only a more complicated way of delivering dose-dense paclitaxel.

  • Optimally debulked patients
  • Stage III ovarian cancer
  • Intraperitoneal or intravenous chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.